As of September 30, 2026, Entera Bio Ltd. carries a market capitalization of 506.11M, placing it among publicly traded companies globally. Its enterprise value stands at 240.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 506.11M |
| Enterprise Value | 240.63M |
Entera Bio Ltd.'s next confirmed earnings release is scheduled for March 26, 2027.
| Earnings Date | 3/26/2027 |
As of September 30, 2026, Entera Bio Ltd. has 173.92M shares outstanding.
| Shares Outstanding | 173.92M |
These figures are as of September 30, 2026.
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.85 |
| P/FCF Ratio | -13.30 |
| P/OCF Ratio | -13.34 |
As of September 30, 2026, Entera Bio Ltd. maintains a current ratio of 128.41, meaning it holds 128.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.14, indicating conservative leverage, while an interest coverage ratio of -6.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 128.41 |
| Quick Ratio | 123.53 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -6.68 |
Over the twelve months ended September 30, 2026, Entera Bio Ltd. posted a negative return on equity (ROE) of -20.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.99, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 22.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -20.33 |
| Return on Assets (ROA) | -19.99 |
| Employee Count | 22.00 |
As of the close on November 16, 2026, Entera Bio Ltd.'s stock has gained approximately 11.44% over the past 52 weeks. The 50-day moving average sits at 2.90, while the 200-day moving average is 1.99.
| 52-Week Price Change | 11.44% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 1.99 |
Over the twelve months ended September 30, 2026, Entera Bio Ltd. generated - - in revenue and converted that into -29.43M in net income, yielding earnings per share of -0.41. EBITDA reached -18.38M, while operating income came in at -18.41M.
| Operating Income | -18.41M |
| Pretax Income | -29.43M |
| Net Income | -29.43M |
| EBITDA | -18.38M |
| EBIT | -18.41M |
| Earnings Per Share (EPS) | -0.41 |
As of September 30, 2026, Entera Bio Ltd. holds 265.88M in cash and equivalents against 397,000.00 in total debt, resulting in a net debt position of -265.88M. Total book value stands at 274.28M, with working capital of 274.31M providing operational flexibility.
| Cash & Cash Equivalents | 265.88M |
| Total Debt | 397,000.00 |
| Net Debt | -265.88M |
| Equity (Book Value) | 274.28M |
| Book Value Per Share | 1.58 |
| Working Capital | 274.31M |
Entera Bio Ltd. produced -15.79M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -51,000.00 in capital expenditures, free cash flow totaled -15.84M - equivalent to -0.22 per share.
| Operating Cash Flow | -15.79M |
| Capital Expenditures | -51,000.00 |
| Free Cash Flow | -15.84M |
| FCF Per Share | -0.22 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -7.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -53.68, meaning Entera Bio Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -53.68 |
| FCF Yield | -7.52 |
As of September 30, 2026, Entera Bio Ltd. has an Altman Z-Score of 110.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 110.31 |
Already premium?